Today's Healthcare Pulse
Allogene Therapeutics CEO David Chang to step down
Allogene Therapeutics announced that chief executive David Chang will leave his role. The news was reported by STAT+ and echoed in a follow‑up piece covering broader pharma updates.
Also developing:
By the numbers: Boston Scientific invests $1.5B for 34% stake in MiRus
A Few Weeks Of This Brain Training Could Protect Your Mind For Decades
A 20‑year study of 2,021 adults over 65 compared memory, reasoning and speed‑training exercises. Only the brief speed‑training protocol, which targets rapid visual processing, reduced dementia diagnoses by 25 %. The benefit persisted only when participants added occasional booster sessions. The findings suggest a low‑cost, time‑limited intervention could protect cognitive health for decades.
New Orleans EMS Misses Response Time Benchmarks as Understaffing Worsens Delays
New Orleans EMS missed national response‑time benchmarks in 71% of incidents, with average arrivals at 17 minutes 45 seconds—almost double the nine‑minute standard. Chronic understaffing, operating at only 60% of budgeted personnel and fielding 17 ambulances instead of the 26 needed,...
Novo May Have Muscle Advantage over Lilly in Weight-Loss Race: Preprint
A new medRxiv pre‑print analyzing nearly 8,000 GLP‑1 patients finds Novo Nordisk’s semaglutide preserves lean body mass better than Eli Lilly’s tirzepatide, despite the latter delivering greater overall weight loss. In the first year, 6.7% of semaglutide users fell into a...
Expanded Access to Investigational Drugs for Treatment Use: Questions and Answers
The FDA issued a final Level 1 guidance titled “Expanded Access to Investigational Drugs for Treatment Use: Questions and Answers,” originally released in June 2016 and updated in October 2017. The document consolidates frequently asked questions about the 2009‑enacted expanded‑access regulations under 21 CFR part 312...
Texas Medical Board Sanctions Three Doctors for Delayed Care That Led to the Deaths of Two Pregnant Women
The Texas Medical Board has disciplined three physicians—Dr. Ali Osman, Dr. William Hawkins and Dr. Andrew Davis—for delayed or inappropriate pregnancy care that resulted in the deaths of two pregnant women. The board cited each doctor for failing to intervene...
Connecticut Judge Refuses to Hit Pause in Multistate Generic-Drug Antitrust Fight
A federal judge in Connecticut denied a request to pause the multistate antitrust lawsuit accusing generic‑drug manufacturers of price‑fixing. The ruling keeps the coordinated MDL active while settlement discussions continue, preserving litigation pressure on the defendants. The case is a...
Policy Watch: FDA Issues Draft Guidance on Genome-Editing Safety
The FDA released a draft guidance urging sponsors to use next‑generation sequencing to evaluate off‑target effects of CRISPR‑Cas9 and other gene‑editing therapies, recommending short‑read or long‑read approaches based on the type of DNA alteration. The guidance dovetails with a February...
Can an LSD Candidate Do for Anxiety What Spravato Did for Depression?
Johnson & Johnson’s 2019 Spravato approval unlocked the pharmaceutical market for psychedelics, proving they can become blockbuster drugs. Definium Therapeutics is now advancing DT120, an LSD‑based candidate for generalized anxiety disorder, after phase 2 data showed a 78% clinical response and...
New Bioengineered Patch Makes Its Own Oxygen to Heal Wounds and Grow Tissue
Researchers at UC Riverside and Rowan University unveiled a self‑oxygenating tissue patch, the Smart Self‑Oxygenating Tissue (SSOT) system, that creates oxygen on‑demand via low‑voltage electrolysis in a conductive hydrogel called BioGel. The BioGel incorporates a choline‑based ionic liquid, boosting stiffness...
Salt Capital and Proparco Acquire Namibian Oncology Centre
Salt Capital and French development finance institution Proparco have jointly acquired The Namibian Oncology Centre (NOC), Namibia’s leading specialist cancer care provider. The acquisition follows NOC’s founding by local clinicians and businesspeople to broaden cancer diagnosis, treatment and care across...
Replimune Cries Foul on Regulatory Flexibility. But Many Americans Want a Stricter FDA
The FDA rejected Replimune’s RP1 melanoma combination therapy twice, citing patient‑population heterogeneity that it says undermines efficacy interpretation. The biotech’s CEO decried the agency’s lack of regulatory flexibility, while a Politico poll revealed most Americans prefer a slower, more rigorous...
‘Bad-Vaxx’ Game Aims to ‘Inoculate’ Kids Against Vaccine ‘Misinformation’
The "Bad Vaxx" video game, launched last year, uses inoculation theory to teach children to resist vaccine misinformation. Researchers published in Scientific Reports claim the game improves players' ability to spot manipulation and reduces sharing of false content. Funding comes...
Revolution Medicines' Daraxonrasib Cuts Pancreatic Cancer Death Risk by 60% – This Week in Biotech #96
Revolution Medicines announced Phase 3 RASolute 302 results for its oral RAS‑ON inhibitor daraxonrasib in second‑line metastatic pancreatic ductal adenocarcinoma. The trial reported a median overall survival of 13.2 months versus 6.7 months with standard chemotherapy, a hazard ratio of 0.40 and a 60%...
Piramal Pharma Solutions Partners with Ajinomoto Bio-Pharma Services to Advance ADC Development and Manufacturing
Piramal Pharma Solutions and Ajinomoto Bio‑Pharma Services have signed a strategic collaboration to accelerate antibody‑drug conjugate (ADC) development and manufacturing. Piramal will refer its customers to Ajinomoto’s AJICAP platform for site‑specific ADC conjugation, while Ajinomoto will direct clients to Piramal...
Kailera Raises $625M IPO in Biotech Record
Kailera Therapeutics completed a $625 million IPO, establishing a new biotech record and eclipsing Moderna’s 2018 $604 million debut. The offering, led by Goldman Sachs, JPMorgan and Morgan Stanley, attracted strong institutional demand and priced above expectations. Proceeds will fund Kailera’s gene‑editing...
FDA Commissioner Makary: Miracle Cancer Cures Are in the Pipeline
FDA Commissioner Marty Makary has announced that "miracle" cancer cures are on the horizon, promising faster FDA approvals and unprecedented transparency in clinical data. He suggests that trials could be completed within months using thousands of volunteers, dramatically shortening the...
Judge Dismisses CVS-Aetna’s Lawsuit Against Radiology Partners
A federal judge in Jacksonville dismissed CVS‑Aetna's lawsuit accusing Radiology Partners of a multi‑phase fraud scheme, granting the radiology group’s motion and barring the insurer from re‑filing the claims. The case centered on alleged misuse of a Florida practice’s tax...
Next Stage of Growth with a New CEO
Resyca BV, a Dutch specialist in soft‑mist inhalation drug delivery, has appointed Deborah Jones as its new chief executive. Jones brings over two decades of senior leadership experience, most recently overseeing business strategy for Proveris Scientific across EMEA and India....
Lilly’s Tirzepatide Sheds Lean Muscle Harder than Novo’s Semaglutide, Study Suggests
A new, pending‑peer‑review study compares Eli Lilly’s tirzepatide with Novo Nordisk’s semaglutide, confirming tirzepatide delivers greater overall weight loss but also leads to a larger reduction in lean body mass. Researchers used dual‑energy X‑ray absorptiometry to quantify fat‑free mass loss, finding up...
Radiologist Pipeline Barely Keeping Pace with Population Growth
A new study in the Journal of the American College of Radiology finds that the radiology workforce is expanding far slower than the U.S. population and overall medical training capacity. Between 2010 and 2024, residency slots rose 33% to 1,449...
New Study Sets Six‑Element Standard for Positive Mental Wellbeing
An international consortium of 122 experts published a new definition of positive mental wellbeing in Nature Mental Health, identifying six core elements. The framework aims to replace fragmented metrics and guide governments, schools, and health systems toward more holistic mental‑health...
How Clinical Trials Validate New Peptide Therapies
Clinical trials are essential for turning promising peptide molecules into reliable therapeutics by confirming that their effects are consistent, measurable, and reproducible across diverse populations. The article outlines how preclinical research defines mechanisms and safety, while Phase I focuses on human...
The Quiet Hospital Financial Crisis Threatening Health Care
The article warns that U.S. hospitals are now facing a silent financial crisis, shifting from pandemic‑driven patient surges to cost‑driven strain. Labor expenses stay high, reimbursement lags inflation, and an aging payer mix erodes margins. Service lines are being cut,...
Buckinghamshire Healthcare NHS Trust Becomes First Trust to Sign up to System C’s Ambient AI Consultations
Buckinghamshire Healthcare NHS Trust has become the first NHS organisation to sign a contract with System C to deploy its CareFlow Ambient AI Outpatient Consultations module, slated to go live in summer 2026. The AI‑driven solution will embed real‑time transcription,...
CDC Data Shows 14% Rise in Supplement‑Linked Illnesses Among Adults 65+
The Centers for Disease Control and Prevention reported a 14% jump in supplement‑related illnesses among adults aged 65 and older over the past year. The rise comes as supplement use remains near‑ubiquitous in this age group, prompting public‑health officials to...
Multiple Myeloma Drug Blenrep Backed for Wider NHS Use
The UK’s health technology regulator NICE has broadened the approved use of GSK’s BCMA‑targeting drug Blenrep, allowing it to be combined with Takeda’s Velcade and dexamethasone for a larger second‑line multiple myeloma population. The new guidance lifts the restriction that...
Radiologists Earning an Average of $571,000, up 9% Year over Year
Radiologists now earn an average of $571,000, marking a 9% increase from the previous year, according to Medscape’s latest physician compensation survey. This places radiology third among the highest‑paid specialties, behind orthopedics ($611,000) and cardiology ($575,000). The rise mirrors a...
Lilly’s Obesity Pill Foundayo Gets 1,390 Prescriptions in Debut Week
Eli Lilly's newly launched oral obesity drug Foundayo filled 1,390 prescriptions in the United States during its debut week ending April 10, according to IQVIA data. By comparison, Novo Nordisk's oral Wegovy recorded 3,071 prescriptions in its first four days...
WHO Calls for Health Systems to Boost Support for Parents and Caregivers
The World Health Organization, together with the Child Health Task Force and the ECD Action Network, announced a global webinar to explore how health services can embed evidence‑based support for parents and caregivers. The event will showcase practical tools and...
Prescription Drug Costs Soaring Under Trump Regime
A Senate Health, Education, Labor and Pensions Committee report, released by Sen. Bernie Sanders, reveals that drugmakers who signed price‑cut agreements with the Trump administration are simultaneously hiking prices on hundreds of other medications. New therapies now launch at an...
New Data Raise Concern About Medicare Quality Payment Program, Radiology Experts Say
A new analysis of CMS Quality Payment Program data from 2017‑2023 reveals that nearly half of the 275 MIPS quality measures are already topped out, and reporting rates remain low across most specialties. Diagnostic radiology and pathology show the highest...
AI and Wearables Achieve 90% Accuracy in Predicting Athlete Injuries
AI-powered wearables are now able to predict injuries in athletes with roughly 90% accuracy, according to recent studies. The technology combines motion analysis, training load, sleep quality and recovery data, offering a proactive alternative to traditional reactive sports medicine.
Women Experience Faster Tau Buildup and Cognitive Decline
Women show greater tau buildup and faster cognitive decline than men in Alzheimer's https://t.co/5GKfzXZPSo https://t.co/8L9wxDsFAp
This Sam Altman-Backed $1.8 Billion Startup Bets AI Can Get Drugs Through Clinical Trials Faster
Formation Bio, backed by Sam Altman and top VCs, has raised $615 million at a $1.8 billion valuation to use AI for faster, cheaper clinical trials. The New York‑based firm plans to acquire a portfolio of about ten early‑stage drug candidates, many stalled...
VR Headset Transports 82‑year‑old Nursing Home Resident to Florence, Boosting Senior Care
Mynd Immersive demonstrated its VR headset to 82‑year‑old Carol Foster at The New Jewish Home, letting her virtually explore Florence. The session underscores how immersive technology is reshaping therapy in senior living facilities across the U.S.
3 Ways to Invest in the Growing GLP-1 Weight Loss Market
The global GLP‑1 receptor agonist market is set to nearly triple, reaching roughly $185 billion by 2033 with a 12.4% compound annual growth rate. Investors can tap the surge through a direct play in Structure Therapeutics, whose aleniglipron candidate posted a...
Goodfire AI and the Billion Dollar Bet on Neural Network Interpretability: Why Reverse Engineering Foundation Models Matters for Health Tech...
Goodfire AI, a San Francisco public‑benefit AI lab, raised a $150 million Series B in February 2026, pushing its valuation to $1.25 billion. Its Ember platform gives developers programmatic access to neural‑network internals, claiming a 58% reduction in large‑language‑model hallucinations at roughly 90 × lower...
The 5 Childhood Illnesses You No Longer Need a GP Appointment For
The NHS has rolled out Pharmacy First in England, allowing parents to seek treatment for five common childhood illnesses directly at local pharmacies without a GP appointment. Eligible conditions include earache (ages 1‑17), sore throat (5+), sinusitis (12+), infected insect...
Blue‑State Hospitals Halt Transgender Youth Care, Fueling National Debate
Hospitals in several blue states have stopped providing gender‑affirming treatment to transgender minors, triggering a fresh political and legal clash. Families who moved seeking supportive care now face abrupt service cuts, while lawmakers and advocates argue the moves threaten established...
Pfizer Unveils Nanoparticle Platform to Sharpen Cancer Treatment
Pfizer disclosed a new nanoparticle platform designed to deliver cancer drugs directly to tumors, promising higher precision and fewer side effects. The initiative is led by Puja Sapra, head of the Targeted Therapeutics Unit in Oncology R&D, and is part...
Viking Therapeutics Gains Strong‑Buy Consensus as Obesity Market Eyes $100B by 2030
Wall Street analysts have given Viking Therapeutics (VKTX) an average brokerage recommendation of 1.33, bordering on a strong buy, as its GLP‑1 obesity candidates move through phase‑3 trials. The stock’s 121% one‑day surge in early 2024 and a $100 billion market...
A Treasure Trove of Food for Thought From Julia Belluz
Julia Belluz’s New York Times essay examines GLP‑1 medicines as broad metabolic tools, not merely weight‑loss drugs. She outlines emerging cardiometabolic, brain‑health, and inflammation benefits while stressing that scientific proof lags behind rapid real‑world adoption. The piece gives weight to patient experiences...
Labcorp and CHOP Launch Pediatric Diagnostics Partnership to Expand Advanced Testing and Drive Clinical Lab Growth
Labcorp and the Children’s Hospital of Philadelphia (CHOP) have formed a strategic partnership to accelerate development and commercialization of pediatric‑specific diagnostics. The collaboration will combine CHOP’s research expertise with Labcorp’s nationwide testing network to bring new molecular and genetic assays...
Can AI Help Us Finally Beat Cancer W/ Dr. Sanjay Juneja, TheOncDoc
In this episode of CareTalk, oncologist Dr. Sanjay Ganesha (TheOncDoc) discusses how advances in AI, immunotherapy, CAR‑T, and early‑detection blood tests are turning cancer from a death sentence into a manageable disease. He shares his personal journey from a vision‑loss...
Bringing New Delivery Methods to Treatments: Q&A with Richard Lowenthal
In March 2025 the FDA cleared ARS Pharmaceutical’s neffy, a needle‑free epinephrine nasal spray, marking the first major delivery innovation for the drug in over 35 years. CEO Richard Lowenthal explained that the spray eliminates needle anxiety, simplifies administration, and improves portability,...
The Turning Point for Oral Biologics: Q&A With Morten Graugaard
Orbis Medicines CEO Morten Graugaard says the FDA’s approval of Icotyde validates oral biologics as a viable drug class. He frames the decision as a proof point that macrocycle chemistry can translate biologic efficacy into a pill, but cautions that...
Photo of the Week: Boston EMS Graduation
Boston EMS graduated 26 new EMTs and promoted eight staff members during a ceremony at Faneuil Hall. The new EMTs completed a six‑month academy and responded to more than 3,000 9‑1‑1 calls. Promotions included two lieutenants and six paramedics, reflecting...
Maxivision Eye Hospitals Charts Aggressive Gujarat Expansion; to Invest ₹150 Cr in 2 Yrs
Maxivision Super Speciality Eye Hospitals announced a ₹150 crore (≈$18 million) investment to double its Gujarat footprint from 10 to 20 hospitals within two years. The Hyderabad‑based chain currently operates in six Gujarat cities and will add five new facilities in Ahmedabad...
The Innovators Working to Make in Vivo Cell Therapy a Reality
First‑in‑human trials of in‑vivo CAR‑T therapies are now underway, delivering therapeutic genes directly inside patients via viral or lipid‑nanoparticle vectors. Big‑pharma interest is evident after AstraZeneca’s $1 bn purchase of EsoBiotec and Eli Lilly’s $2.4 bn acquisition of Orna Therapeutics, despite limited clinical...
Microplastics Are Showing Up In Early Pregnancy — Here Are The Biggest Sources
Researchers examined chorionic villi from 31 first‑trimester pregnancies and found microplastics in every sample. Women who suffered unexplained miscarriage had significantly higher concentrations—273 µg/g versus 226 µg/g in controls. The plastics were primarily PVC, polyethylene, polystyrene and polypropylene, with bottled water and...